Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
Last trade$3.94
Day change-$0.18 (-4.37%)
Day range$3.90 – $4.14
Volume202,086
Market cap$331M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$330.85M
Price / earnings
—
Price / book
1.88×
Price / sales
—
EV / sales
—
EV / EBITDA
-1.36×
Profitability
Earnings per share
-$1.94
Return on assets
-77.43%
Return on equity
-88.46%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
8×
Quick ratio
8×
Cash ratio
3.91×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$140.57M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for AVIR, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$6.92M
$6.95M
$6.87M
$7.12M
$7.22M
$9.07M
$9.46M
$13.36M
Research and development
$27.09M
$28.15M
$41.13M
$47.82M
$38.35M
$32.28M
$29.58M
$25.67M
Total operating expenses
$34.01M
$35.1M
$48.01M
$54.93M
$45.57M
$41.35M
$39.04M
$39.03M
Operating income
-$34.01M
-$35.1M
-$48.01M
-$54.93M
-$45.57M
-$41.35M
-$39.04M
-$39.03M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$32.12M
-$32.91M
-$45.39M
-$51.64M
-$41.85M
-$36.95M
-$34.07M
-$33.32M
Income taxes
$38K
$24K
$50K
-$6.77M
$196K
$207K
$203K
$225K
Net income
-$32.16M
-$32.93M
-$45.44M
-$44.87M
-$42.05M
-$37.16M
-$34.27M
-$33.54M
Net income attributable to common shareholders
-$32.16M
-$32.93M
-$45.44M
-$44.87M
-$42.05M
-$37.16M
-$34.27M
-$33.54M
EBITDA
-$33.91M
-$35M
-$47.9M
-$54.83M
-$45.46M
-$41.24M
-$38.94M
-$38.92M
Basic earnings per share
-$0.40
-$0.41
-$0.57
-$0.58
-$0.53
-$0.44
-$0.40
-$0.40
Diluted earnings per share
-$0.40
-$0.41
-$0.57
-$0.58
-$0.53
-$0.44
-$0.40
-$0.40
Recent news
Company coverage with links to the original publishers.
Atea Pharmaceuticals announced Phase 1 results demonstrating that its fixed-dose combination regimen of bemnifosbuvir and ruzasvir (BEM/RZR) for hepatitis C virus treatment has a low risk of drug-drug interactions with commonly used medications like omeprazole and rosuvastatin. The company also presented preclinical data showing AT-587, a potential first-in-class direct-acting antiviral for hepatitis E virus, exhibits high antiviral potency and in vivo efficacy, with plans to initiate first-in-human studies mid-2026.
Atea Pharmaceuticals announced preclinical results showing AT-587 and AT-2490 are potent inhibitors of Hepatitis E Virus (HEV), demonstrating 30-150 fold greater potency compared to sofosbuvir and ribavirin. The company plans to initiate Phase 1 clinical trials for AT-587 mid-2026, addressing an unmet medical need as no antivirals are currently approved for HEV treatment.
Atea Pharmaceuticals presented modeling data showing their combination drug regimen of bemnifosbuvir and ruzasvir could potentially provide a short-duration, highly effective treatment for hepatitis C virus, with near-complete viral inhibition and a modeled cure time of 7-8 weeks.
Atea Pharmaceuticals will host a conference call on November 12, 2025, to discuss third quarter financial results and provide a business update, focusing on their antiviral drug development platform and HCV treatment research.
Atea Pharmaceuticals will host a conference call on August 7, 2025, to discuss second quarter 2025 financial results and provide a business update, focusing on their HCV treatment development program.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.